Debevoise & Plimpton LLP is advising Guggenheim Securities, LLC as financial advisor to Menlo Therapeutics (Nasdaq: MNLO) in its merger with Foamix Pharmaceuticals Ltd (Nasdaq: FOMX), creating a combined company focused on the development and commercialization of therapeutics to serve patients in the dermatology space. The deal is expected to close by late Q1/early Q2 of 2020. Read the company press release here.
Guggenheim Securities is the investment banking and capital markets business of Guggenheim Partners, a global investment and advisory firm with more than $265 billion in assets under management.
Menlo is a late-stage biopharmaceutical company focused on the development of serlopitant. Foamix is a specialty pharmaceutical company, committed to providing new options for patients by bringing innovative solutions to the field of dermatology.
The Debevoise team is led by M&A partner Andrew L. Bab and includes M&A associates Claire Hansen Suni and Gabriel Pollack.